Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 6/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14788664 | 0.92 | GPR84 (0.46) | DHODHTP53LMNARXFP1CNR1 | |
| SCHEMBL3788617 | 0.87 | TP53 (0.42) | DHODHTP53LMNARXFP1CNR1 | |
| SCHEMBL2281584 | 0.87 | NAMPT (0.49) | DHODHTP53LMNASMN1; SMN2 | |
| SCHEMBL3788803 | 0.87 | KMT2A (0.44) | TP53LMNARXFP1CNR1THRB | |
| SCHEMBL3790086 | 0.85 | TP53 (0.44) | DHODHTP53LMNARXFP1THRB | |
| SCHEMBL12803747 | 0.85 | KMT2A (0.47) | TP53LMNARXFP1CNR1THRB | |
| SCHEMBL27755776 | 0.85 | TP53 (0.42) | TP53LMNARXFP1CNR1THRB | |
| SCHEMBL3786276 | 0.84 | EGLN1 (0.42) | TP53LMNARXFP1CNR1THRB | |
| SCHEMBL3809865 | 0.82 | MMP13 (0.42) | TP53LMNAMAPT | |
| SCHEMBL1351560 | 0.82 | CSNK2A1 (0.43) | DHODHCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252806-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2012-10-04 | — | — | US | disclosed |
| EP-2391623-A1 | INHIBITORS OF AKT ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010088177-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252806-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3CG | DHODH 2427/4885TP53 398/4885LMNA 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.